Covid-19 bioweapons and the Defense Production Act of 1950
This is a repost of Bailiwick Substack blog by Katherine Watt. First up some commentary from me.
Here are more facts that show you how the US government has been co-opted by the giant pharmaceutical companies who have now been folded into the Federal government. They are the ones in charge along with the heads of FEMA and HHS who have been implementing these emergency orders.
Also in today’s post we have a video detailing some of the documents that reveal that it was the Pentagon and DOD who were in charge of the vaccination program from the very beginning.
There will be NO RELIEF in the US courts as the public health laws have been rewritten to make sure that everyone from big pharma on down to the nurses administering the shots are immune from prosecution. Now for Katherines very informative blog.
Karen Kingston just put up another piece about the contract and it’s getting weird because it seems like we’re talking about two different things entirely.
My reply, expanded:
I think the divergence lies in the difference between a pharmaceutical corporation operating as a private, commercial business, and a pharmaceutical corporation that has been folded into the government’s national security complex through invoking of the Defense Production Act of 1950, PL 81-774, 64 Stat. 798.
Nov. 22, 2021 – Domestic Funding for COVID-19 Vaccines: An Overview, Congressional Research Service
Research and Development, Manufacture, and Purchase
COVID-19 vaccine R&D, manufacture, and purchase have been largely supported by a collaboration among several federal agencies, including the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of HHS, and DOD— formerly Operation Warp Speed (OWS) and now the Countermeasures Acceleration Group (CAG).
Six vaccines were chosen for coordinated federal support under OWS. Some vaccine R&D has been supported by NIH, BARDA, and DOD separately from the OWS/CAG efforts.
NIH and DOD: FY2020 and FY2021 supplemental appropriations to NIH and DOD for COVID-19-related R&D can fund vaccine R&D. In the FY2020 and FY2021 supplemental appropriations acts, NIH received over$1.5 billion, available until September 30, 2024, broadly for COVID-19 related research.
The CARES Act (P.L. 116- 136) provided DOD with $415 million for COVID-19 medical R&D in the Defense Health Program account with some flexibility to reallocate other funds toward R&D.
BARDA and Other R&D, Manufacture, and Purchase:
In the FY2020 and FY2021 supplemental appropriations acts, over $50 billion in Public Health and Social Services Emergency Fund (PHSSEF) funding, available until September 30, 2024, is designated for a broad set of medical countermeasures and surge capacity purposes, including for the development, manufacture, and purchase of vaccines and related supplies.
The PHSSEF account funds BARDA, the main entity that has awarded large funding agreements to pharmaceutical companies for vaccine development, manufacture,and purchase.
Not less than $23.2 billion is set aside for BARDA in the FY2020 andFY2021 supplemental appropriations that can be used for vaccine-related efforts.
[American Rescue Plan Act, PL 117-2] further provides two relevant mandatory appropriations:
(1) in Section 2303, $6.05 billion, available until expended, to HHS for R&D, manufacturing, production, and purchase of vaccines and other medical products—available for COVID-19, SARS-CoV-2 or its variants, and any disease with potential for creating a pandemic; and
(2) in Section 3101, $10 billion, available until September 30, 2025, for activities under the Defense Production Act (DPA) for the purchase, production and distribution of medical supplies, including vaccines and related supplies, among others. Both of these ARPA appropriations have been assigned to HHS accounts—the first to PHSSEF and the second to a new HHSDPA [Health and Human Services Defense Production Act] account.
For more on the HHSDPA, see March 27, 2020 Executive Order 13911, Delegating Additional Authority Under the Defense Production Act With Respect to Health and Medical Resources To Respond to the Spread of COVID–19, and Department of Commerce Bureau of Industry and Security June 30, 2022 PowerPoint:
The pharmaceutical corporations have essentially turned into a branch of the federal government, whose agents have been granted sovereign immunities and set beyond ordinary judicial proceedings, short of treason, sedition and bioterrorism prosecutions. Source is HERE.
You can support this ministry and keep us on the internet using the links below. Patreon and PayPal are gone so now we have Cash App and Buy me a Coffee as our online options. The new buy me a coffee link is below.
Cash App ID: $jstorm212